MageA1-TCR gene therapy - MediGene

Latest Information Update: 26 Sep 2017

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator MediGene AG
Class Immunotherapies
Mechanism of Action Gene modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Multiple myeloma

Most Recent Events

06 Sep 2017 Medigene AG files CTA applicationin Germany for Multiple myeloma
06 Sep 2017 MediGene plans a phase I/II trial for Multiple myeloma in Germany in December 2017
17 Mar 2017 MediGene plans a phase I/II trial for an undisclosed indication in the second half of 2018 (MediGene pipeline, March 2017)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.